Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2016 01:00 ET | Source: Celyad

Celyad Receives the First US Patent Covering a Method of Producing Allogeneic TCR-Deficient CAR T-Cells

MONT-SAINT-GUIBERT, Belgium, March 02, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
February 29, 2016 01:00 ET | Source: Celyad

Celyad to Host an Immuno-Oncology R&D Analyst Day on March 24th in New York City

Expert panel to present on next generation T-Cell therapy using the natural killer cell receptor NKG2DCelyad to present its immune-oncology portfolio with emphasis on the natural killer receptor...
February 25, 2016 01:00 ET | Source: Celyad

Celyad Successfully Completes Safety Follow-Up of the Second Dose Level of Patients in Its NKR-2 Trial and Enrolls First Patient in the Third Dose Level

The trial is a dose escalation study evaluating safety and feasibility of T-cell Natural Killer Receptor NKG2D in patients with acute myeloid leukemia or multiple myeloma.No dose limiting toxicity...
February 08, 2016 01:00 ET | Source: Celyad

Prof. William Wijns Appointed to Chair the Scientific Committee That Will Oversee the CHART-1 Data Analysis and Dissemination Plan.

MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
February 03, 2016 01:00 ET | Source: Celyad

Celyad Appoints Dr. Richard Mountfield as Vice-President of Global Regulatory Affairs

MONT-SAINT-GUIBERT, Belgium, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
January 20, 2016 01:00 ET | Source: Celyad

Celyad Announces 2016 Financial Calendar

MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
January 05, 2016 01:00 ET | Source: Celyad

Celyad Completes 30-Day Safety Follow-Up of First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial

No dose limiting toxicity related to the investigational treatment reported at 30 days post treatment of the first patient of the second dose-level;The trial is a dose escalation study evaluating...
December 23, 2015 01:00 ET | Source: Celyad

Celyad to Address US Institutional Investors in January at J.P. Morgan Healthcare Conference

MONT-SAINT-GUIBERT, Belgium, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
December 21, 2015 01:00 ET | Source: Celyad

Celyad Receives Clearance From the US FDA on Its CHART-2 Phase III IND

MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
December 16, 2015 01:00 ET | Source: Celyad

Celyad Announces the Publication of Its CHART-1 Trial Design Methods Paper in the European Journal of Heart Failure

MONT-SAINT-GUIBERT, Belgium, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with...